Trastuzumab/paclitaxel-induced pneumonitis in breast cancer

Article metrics loading...

/content/journals/10.5339/qmj.2024.qitc.12

2024-03-25

2024-11-09

Full text loading...

/deliver/fulltext/qmj/2024/2/qmj.qitc.12.html?itemId=/content/journals/10.5339/qmj.2024.qitc.12&mimeType=html&fmt=ahah

References

Rivera-Ortega P, Molina-Molina M. Interstitial lung diseases in developing countries. Annals of Global Health. 2019; 85:(1):4. https://doi.org/10.5334/aogh.2414. PMID: 30741505; PMCID: PMC7052338.
[Google Scholar]
Conte P, Ascierto PA, Patelli G, Danesi R, Vanzulli A, Sandomenico F, et al.. Drug-induced interstitial lung disease during cancer therapies: Expert opinion on diagnosis and treatment. ESMO Open. 2022; 7:(2):100404. https://doi.org/10.1016/j.esmoop.2022.100404. PMID: 35219244; PMCID: PMC8881716.
[Google Scholar]

/content/journals/10.5339/qmj.2024.qitc.12

Trastuzumab/paclitaxel-induced pneumonitis in breast cancer

Qatar Medical Journal 2024, 12 (2024); https://doi.org/10.5339/qmj.2024.qitc.12

/content/journals/10.5339/qmj.2024.qitc.12

Data & Media loading...

Keyword(s): Breast cancer treatment, Drug-induced pneumonitis, Interstitial Lung Disease (ILD), Paclitaxel and Trastuzumab

oa Trastuzumab/paclitaxel-induced pneumonitis in breast cancer